Treatment of Myelofibrosis with 13q Deletion
Treat myelofibrosis with 13q deletion according to standard risk-stratified management protocols, as 13q deletion does not independently alter treatment selection in myelofibrosis. The presence of 13q deletion is not specifically addressed in current myelofibrosis treatment guidelines and does not constitute an adverse cytogenetic abnormality that would modify therapeutic approach 1.
Risk Stratification Drives Treatment Decisions
Treatment of myelofibrosis is determined by:
- Risk category (using MIPSS70+ version 2.0 or GIPSS scoring systems)
- Predominant clinical manifestations (anemia, splenomegaly, constitutional symptoms)
- Transplant eligibility
- Presence of high-risk mutations (SRSF2, ASXL1, U2AF1-Q157) or very high-risk cytogenetics
The very high-risk cytogenetic abnormalities that do alter prognosis include: -7, inv(3), i(17q), +21, +19, 12p-, and 11q- 2. 13q deletion is not among these adverse cytogenetic markers 1.
Treatment Algorithm by Risk Category
Low and Very Low Risk (10-year survival 56-92%)
- Observation alone is appropriate 2
- Initiate treatment only when symptoms develop
Intermediate-1 Risk (10-year survival 30%)
- Allogeneic stem cell transplant (AHSCT) should be considered if any of the following are present 1:
- Refractory transfusion-dependent anemia
- Peripheral blood blasts >2%
- Adverse cytogenetics (which does not include 13q deletion)
- High-risk mutations (SRSF2, ASXL1, U2AF1-Q157)
- Otherwise, symptom-directed therapy
High and Very High Risk (10-year survival 0-13%)
- AHSCT is the preferred treatment for transplant-eligible patients 1, 2
- This is the only curative option
Symptom-Directed Palliative Therapy
When treatment is indicated based on symptoms rather than risk alone:
For Splenomegaly and Constitutional Symptoms
JAK inhibitors are first-line therapy 1:
- Momelotinib may be preferred as initial JAK inhibitor to address the triad of anemia, splenomegaly, and constitutional symptoms simultaneously 3
- Ruxolitinib is recommended for intermediate-2 or high-risk disease with splenomegaly; for intermediate-1 risk, use only if highly symptomatic 1
- Pacritinib for severe thrombocytopenia (platelet count <50 × 10⁹/L) 2
- Fedratinib for ruxolitinib-resistant or intolerant patients 2
For Anemia (Hemoglobin <10 g/dL)
Non-JAK inhibitor therapies are preferred initially if splenomegaly/symptoms don't require treatment 3:
- Erythropoiesis-stimulating agents if EPO level <125 mU/mL, no significant splenomegaly, and not transfusion-dependent 4
- Danazol 400-600 mg daily for at least 6 months (35% response rate) 4
- Androgens (nandrolone, oxymetholone) with 30-60% response 4
- Lenalidomide with prednisone (19% response) 4
Important caveat: Note that lenalidomide as single agent is specifically the treatment of choice for MF patients with 5q deletion, not 13q deletion 4.
For Drug-Refractory Disease
- Splenectomy for symptomatic splenomegaly unresponsive to JAK inhibitors (5-10% perioperative mortality, 25% morbidity) 4
- Splenic irradiation only for poor surgical candidates (transient benefit, high cytopenia risk) 4
Key Clinical Pitfalls
Do not confuse 13q deletion in myelofibrosis with its significance in other hematologic malignancies (e.g., multiple myeloma or chronic lymphocytic leukemia where it has different prognostic implications)
The 13q deletion in myelofibrosis typically involves loss of RB1, D13S319, and D13S25 loci 5, but this does not translate into the adverse prognostic impact seen with the specific very high-risk cytogenetic abnormalities listed above
Avoid delaying AHSCT in transplant-eligible patients with high/very high-risk disease or intermediate-1 risk with adverse features, regardless of cytogenetic findings including 13q deletion
JAK inhibitors provide symptom control and quality of life improvement but are not disease-modifying—they do not significantly alter natural history or prevent leukemic transformation 6, 7